Articles tagged "Renal function"

2018 American Transplant Congress
Renal and Bone Safety in Post Liver Transplant Patients with Chronic Kidney Disease Receiving Tenofovir Alafenamide for HBV Prophylaxis
E. Gane,¹ B. George,¹ S. Munn,¹ H. Wang,² V. Suri,² A. Gaggar.²
¹Auckland City Hospital, Auckland, New Zealand; ²Gilead Sciences, Foster City, CA.
Background and Aims: Chronic Hepatitis B (CHB) remains a leading indication for orthotopic liver transplantation (OLT) globally. Common complications following OLT include renal dysfunction secondary…
2018 American Transplant Congress
Robotic Assisted Live Donor Kidney Transplantation – Technique and Outcomes
H. Pahari,¹ B. Waldman,² J. Stracke,¹ L. Malinzak,¹ J. Denny,¹ D. Kim,¹ W. Jeong,³ M. Menon,³ A. Yoshida.¹
¹Transplant Surgery, Henry Ford Hospital, Detroit, MI; ²Wayne State University, Detroit, MI; ³Urology, Henry Ford Hospital, Detroit, MI.
Background: Robotic assisted kidney transplantation (RAKT) is now a feasible minimally invasive option in place of open living donor kidney transplant (OKT). Here, we briefly…
2018 American Transplant Congress
Long-Term Outcomes of a Steroid-Free, Belatacept-Based Immunosuppressive Regimen Plus Sirolimus Using Alentuzumab Induction in Renal Transplantation
A. Guasch,¹ A. Ghali,¹ S. Mead,¹ A. Mehta,¹ H. Xu,² A. Kirk.²
¹Emory Transplant Center, Emory University, Atlanta, GA; ²Dept of Surgery, Duke University, Durham, NC.
The toxicities of CNIs and steroids have a negative impact on kidney transplantation. Belatacept is a safe, non-nephrotoxic alternative to CNIs, that may lead to…
2018 American Transplant Congress
Novel Vascular Inflow Offers Renal Transplantation to Recipients with Severe Central and Peripheral Vascular Disease
S. Mao,¹ E. Giorgakis,² A. Moss,² T. Taner.¹
¹William J. von Liebig Center for Transplantation, Mayo Clinic, Rochester, MN; ²Transplantation Surgery, Mayo Clinic, Phoenix, AZ.
Background: Absence of suitable implant locations for donor renal vessels may be a major problem in patients with significant central and peripheral vascular disease. We…
2018 American Transplant Congress
Prolonged-Release Tacrolimus Dosing in De Novo Kidney Transplantation: Randomized, Open-Label, Pilot Study
Y. Kim,¹ Y. Chiang,² S. Kim,³ M. Kim,⁴ S. Park,⁵ S. Wu,⁶ K. Horita,⁷ Y. Nakashima,⁷ H. Jiang,⁸ D. Han.¹
¹Asan Medical Center, Seoul, Korea; ²Chang Gung Memorial Hospital-Linkou, Taoyuan City, Taiwan; ³Samsung Medical Center, Seoul, Korea; ⁴Severance Hospital, Seoul, Korea; ⁵Dongsan Medical Center, Daegu, Korea; ⁶Tri-Service General Hospital, Taipei City, Taiwan; ⁷Astellas Pharma, Inc., Tokyo, Japan; ⁸Astellas Pharma, Inc., Maao, Singapore.
A multicenter, randomized, open-label, parallel-group, pilot, 52-wk study in Asian countries that assessed renal function, efficacy, and safety of low vs standard-dose prolonged-release tacrolimus (PRT)…
2018 American Transplant Congress
Everolimus with Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplant Recipients: Efficacy and Safety Outcomes from the TRANSFORM Study
S. Mulgaonkar,¹ J. Pascual,¹ S. Chadban,¹ H. Tedesco,¹ S. Berger,¹ Y. Qazi,¹ C. Legendre,¹ N. Basic-Jukic,¹ P. Bernhardt,² F. Vincenti.¹
¹TRANSFORM Study Group, Livingston; ²Novartis Pharma AG, Basel, Switzerland.
Purpose: Everolimus (EVR)-facilitated calcineurin inhibitor (CNI) reduction regimens help prevent long-term CNI nephrotoxicity in kidney transplant recipients (KTxRs). TRANSFORM (NCT01950819) is the largest study in…
2018 American Transplant Congress
Estimated GFR for Living Kidney Donor Evaluation before and after Donor Nephrectomy
Y. Kakuta,¹ M. Okumi,¹ R. Imamura,² N. Ichimaru,² S. Takahara,² H. Ishida,¹ K. Tanabe.¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan; ²Urology, Osaka Graduate School of Medicine, Suita, Osaka, Japan.
BackgroundKidney transplantation from living donors is an important treatment for patients with kidney failure. An accurate evaluation of renal function must be conducted before and…
2018 American Transplant Congress
Superior Renal Function with CNI-Free Everolimus over Standard CNI-Based Regimen: 18 Months Data from the Randomized, Multi-Center MANDELA Trial in De Novo Heart Transplant Recipients
M. J. Barten,¹ S. W. Hirt,¹ J. Garbade,¹ C. Bara,¹ A. Doesch,¹ C. Knosalla,¹ C. Grinninger,¹ J. Stypmann,¹ C. Sieder,² M. Junge,² U. Schulz.¹
¹Mandela Study Group, Germany; ²Novartis, Pharma, Germany.
Purpose: The MANDELA study (NCT00862979) was designed to assess the benefit on renal function of either CNI-free or CNI-minimized EVR-based regimen after early conversion of…
2018 American Transplant Congress
Long-Term Outcomes of Liver Transplantation in Patients with Pre-Transplant Renal Dysfunction Treated with Induction Therapy and Delayed Reduced De Novo Once-Daily Tacrolimus
M. Gastaca,¹ J. Bustamante,² A. Ventoso,¹ J. Fernandez,² P. Ruiz,¹ M. Testillano,² M. Prieto,¹ P. Salvador,² I. Palomares,¹ M. Senosiain,² M. Suarez,² A. Valdivieso.¹
¹Hepatobiliary Surgery and Liver Transplant Unit, Cruces University Hospital, Bilbao, Spain; ²Hepatology Unit, Cruces University Hospital, Bilbao, Spain.
AIM: To describe the long-term outcome of liver transplantation (LT) in patients with pre-transplant renal dysfunction treated with induction therapy and delayed reduced de novo…
2017 American Transplant Congress
Post-Liver Transplant (LT) Early Allograft Dysfunction (EAD) Modulates the Effect of Pre-LT Kidney Function on Post-LT Survival.
H. Wadei, M. Mai, B. Taner, K. Croome, A. Keaveny, L. Mai, D. Lee.
Transplant, Mayo Clinic, Jackosonville, FL
The impact of EAD on post-LT renal recovery remains unknown. Aim: To assess the impact of post-LT EAD on renal recovery and post-LT survival. Methods:…